布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病患者后的维奈托克巩固治疗
Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia.
作者信息
Heyman Benjamin, Choi Michael, Kipps Thomas J
机构信息
Department of Medicine Division of Regenerative Medicine UC San Diego Moores Cancer Center UC San Diego San Diego California USA.
Department of Medicine Division of Hematology/Oncology UC San Diego San Diego California USA.
出版信息
EJHaem. 2025 Jun 25;6(4):e70085. doi: 10.1002/jha2.70085. eCollection 2025 Aug.
INTRODUCTION
Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long-term side effects.
METHODS
We performed a retrospective analysis of venetoclax consolidation of 20 patients with CLL after initial BTKi discontinuation. Patients were administered either single-agent venetoclax or in combination with obinutuzumab.
RESULTS
The best peripheral blood minimal residual disease (MRD) response was undetectable MRD, occurring in 89% of patients. With a median follow-up of 47.4 months, both the median progression-free survival and time-to-next treatment were not reached.
CONCLUSION
Venetoclax consolidation after BTKi is a feasible treatment strategy for patients with CLL, with encouraging efficacy deserving further study. : N/A.
引言
布鲁顿酪氨酸激酶抑制剂（BTKi）是治疗慢性淋巴细胞白血病（CLL）的高效疗法，但可能导致长期副作用。
方法
我们对20例初始停用BTKi后的CLL患者进行了维奈克拉巩固治疗的回顾性分析。患者接受单药维奈克拉治疗或与奥妥珠单抗联合治疗。
结果
最佳外周血微小残留病（MRD）反应为未检测到MRD，89%的患者出现此反应。中位随访47.4个月时，中位无进展生存期和至下次治疗时间均未达到。
结论
BTKi治疗后使用维奈克拉巩固治疗对CLL患者是一种可行的治疗策略，其疗效令人鼓舞，值得进一步研究。：无。
Zotero 插件